U.S. market Closed. Opens in 11 hours 44 minutes

FDMT | 4D Molecular Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue20.72M3.13M18.04M13.61M6.99M14.13M5.79M
Cost of Revenue5.75M3.88M3.02M53.04M38.72MN/AN/A
Gross Profit14.97M-751.00K15.02M-39.43M-31.73M14.13MN/A
Operating Expenses127.84M113.16M89.37M70.28M52.61M24.53M17.06M
Selling, General & Admin30.75M32.91M28.01M17.24M13.89M6.17M3.49M
Research & Development97.10M80.25M61.36M53.04M38.72M18.36M13.57M
Other Operating Expenses-181.00K2.54M16.00K-181.00K-46.00K-2.00KN/A
Operating Income-112.87M-110.03M-71.33M-56.66M-50.76M-10.40M-11.27M
Other Expenses / Income12.03M2.54M16.00K-29.00K1.46M-2.00K49.00K
Before Tax Income-100.84M-107.49M-71.32M-56.69M-49.31M-9.55M-11.22M
Income Tax Expenses5.58M-6.42M-3.02M-152.00K3.63M848.00KN/A
Net Income-100.84M-101.08M-68.30M-56.54M-52.94M-9.55M-11.22M
Interest ExpensesN/A-6.42MN/AN/AN/AN/AN/A
Basic Shares Outstanding39.13M32.35M27.73M26.68M26.49M12.52M14.84M
Diluted Shares Outstanding39.13M32.35M27.73M26.68M26.49M12.52M14.84M
EBITDA-107.12M-110.03M-71.33M-55.22M-39.49M-9.70M-10.60M
EBITDA Margin-516.90%-3,516.52%-395.46%-405.68%-565.22%-68.66%-183.02%
EBIT-95.26M-113.91M-71.32M-56.69M-49.31M-8.70M-11.22M
EBIT Margin-459.66%-3,640.52%-395.37%-416.49%-705.78%-61.59%-193.83%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙